P. 1
Intestinal Cancer ' Pipeline Review, H2 2012

Intestinal Cancer ' Pipeline Review, H2 2012

Views: 0|Likes:
Published by Antonio Guiseppe
Intestinal Cancer ' Pipeline Review, H2 2012

Summary

Global Markets Direct's, 'Intestinal Cancer - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Intestinal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Intestinal Cancer. Intestinal Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
- A snapshot of the global therapeutic scenario for Intestinal Cancer.- A review of the Intestinal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.- Coverage of products based on various stages of development ranging from discovery till registration stages.- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.- Coverage of the Intestinal Cancer pipeline on the basis of route of administration and molecule type.- Key discontinued pipeline projects.- Latest news and deals relating to the products.

Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Intestinal Cancer.- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.- Devise corrective measures for pipeline projects by understanding Intestinal Cancer pipeline depth and focus of Indication therapeutics.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Intestinal Cancer ' Pipeline Review, H2 2012

Summary

Global Markets Direct's, 'Intestinal Cancer - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Intestinal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Intestinal Cancer. Intestinal Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
- A snapshot of the global therapeutic scenario for Intestinal Cancer.- A review of the Intestinal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.- Coverage of products based on various stages of development ranging from discovery till registration stages.- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.- Coverage of the Intestinal Cancer pipeline on the basis of route of administration and molecule type.- Key discontinued pipeline projects.- Latest news and deals relating to the products.

Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Intestinal Cancer.- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.- Devise corrective measures for pipeline projects by understanding Intestinal Cancer pipeline depth and focus of Indication therapeutics.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

More info:

Categories:Types, Business/Law
Published by: Antonio Guiseppe on Jan 26, 2013
Copyright:Attribution Non-commercial

Availability:

Read on Scribd mobile: iPhone, iPad and Android.
download as PDF, TXT or read online from Scribd
See more
See less

05/14/2014

pdf

text

original

Intestinal Cancer ' Pipeline Revi ew, H2 2012

Intestinal Cancer ' Pipeline Review, H2 2012 Summary Global Markets Direct's, 'Intestinal Cancer - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Intestinal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Intestinal Cancer. Intestinal Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Intestinal Cancer. - A review of the Intestinal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Intestinal Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy

1

Intestinal Cancer ' Pipeline Revi ew, H2 2012

- Identify and understand important and diverse types of therapeutics under development for Intestinal Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Intestinal Cancer pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 13 Introduction 14 Global Markets Direct Report Coverage 14 Intestinal Cancer Overview 15 Therapeutics Development 16 An Overview of Pipeline Products for Intestinal Cancer 16 Intestinal Cancer Therapeutics under Development by Companies 18 Intestinal Cancer Therapeutics under Investigation by Universities/Institutes 31 Late Stage Products 49 Comparative Analysis 49 Mid Clinical Stage Products 50 Comparative Analysis 50

2

Intestinal Cancer ' Pipeline Revi ew, H2 2012

Early Clinical Stage Products 51 Comparative Analysis 51 Discovery and Pre-Clinical Stage Products 52 Comparative Analysis 52 Intestinal Cancer Therapeutics ' Products under Development by Companies 53 Intestinal Cancer Therapeutics ' Products under Investigation by Universities/Institutes 70 Companies Involved in Intestinal Cancer Therapeutics Development 106 Johnson & Johnson 106 F. Hoffmann-La Roche Ltd. 107 Kyowa Hakko Kirin Co., Ltd. 108 Abbott Laboratories 109 Amgen Inc. 110 AstraZeneca PLC 111 Eli Lilly and Company 112 Viralytics Ltd. 113 GlaxoSmithKline plc 114 Bioniche Life Sciences, Inc. 115 Tekmira Pharmaceuticals Corp. 116 Gilead Sciences, Inc. 117 Daiichi Sankyo Company, Ltd 118 AbGenomics International, Inc. 119 Oxford BioMedica plc 120 YM BioSciences Inc. 121 Celltrion, Inc. 122 Prolexys Pharmaceuticals, Inc. 123 Bio-Path Holdings, Inc. 124 BioSante Pharmaceuticals, Inc. 125 Histogen, Inc. 126 Novartis AG 127 Geistlich Pharma AG 128 Aphios Corporation 129

3

Intestinal Cancer ' Pipeline Revi ew, H2 2012

Astellas Pharma Inc. 130 Chong Kun Dang Pharmaceutical 131 Eisai Co., Ltd. 132 Nippon Kayaku Co., Ltd. 133 Taiho Pharmaceutical Co., Ltd. 134 Teva Pharmaceutical Industries Limited 135 Yakult Honsha Co., Ltd. 136 Enzon Pharmaceuticals, Inc. 137 Alfacell Corporation 138 Bayer AG 139 4SC AG 140 Neogenix Oncology Corporation 141 Alchemia Limited 142 EntreMed, Inc. 143 Celldex Therapeutics, Inc. 144 Enzo Biochem, Inc. 145 AEterna Zentaris Inc. 146 ImmunoCellular Therapeutics, Ltd. 147 IMMUNOMEDICS, INC 148 Idera Pharmaceuticals, Inc. 149 Lorus Therapeutics Inc 150 Bio-Bridge Science, Inc. 151 Bionomics Limited 152 Neuren Pharmaceuticals Limited 153 Northwest Biotherapeutics, Inc. 154 Novogen Limited 155 Cleveland BioLabs, Inc. 156 Compugen Ltd. 157 Paladin Labs Inc. 158 Patrys Limited 159 Critical Outcome Technologies Inc. 160

4

Intestinal Cancer ' Pipeline Revi ew, H2 2012

Curis, Inc. 161 Cytokinetics, Inc 162 Telik, Inc. 163 Poniard Pharmaceuticals, Inc. 164 Regeneron Pharmaceuticals, Inc. 165 Dendreon Corporation 166 Choongwae Pharma Corp 167 Green Cross Corporation 168 MOLOGEN AG 169 Innocell Corporation 170 CrystalGenomics, Inc. 171 BioAlliance Pharma SA 172 Sareum Holdings plc 173 Transgene Biotek Ltd 174 Rexahn Pharmaceuticals, Inc. 175 MabVax Therapeutics, Inc. 176 Oryzon 177 Antisense Pharma GmbH 178 Chipscreen Biosciences Ltd 179 Supratek Pharma Inc. 180 Bionucleon Srl 181 Actinium Pharmaceuticals, Inc. 182 Actis Biologics, Inc 183 Multimmune GmbH 184 Nerviano Medical Sciences S.r.l. 185 Med Discovery SA 186 immatics biotechnologies GmbH 187 Provecs Medical GmbH 188 Alethia Biotherapeutics Inc. 189 Coronado Biosciences, Inc. 190 MacroGenics, Inc. 191

5

Intestinal Cancer ' Pipeline Revi ew, H2 2012

ACT Biotech, Inc. 192 OncoMed Pharmaceuticals, Inc. 193 PledPharma AB 194 Boston Biomedical, Inc. 195 DanDrit Biotech A/S 196 PDS Biotechnology Corporation 197 AlphaVax, Inc. 198 Azaya Therapeutics, Inc. 199 Merrimack Pharmaceuticals, Inc. 200 CritiTech, Inc. 201 Deciphera Pharmaceuticals, LLC 202 ProNAi Therapeutics, Inc. 203 Mersana Therapeutics, Inc. 204 Affichem 205 Advenchen Laboratories, LLC 206 MolMed S.p.A. 207 Pharminox Limited 208 NovaLead Pharma Pvt. Ltd. 209 Vaccinogen, Inc. 210 Globeimmune, Inc. 211 Etubics Corporation 212 NewLink Genetics Corporation 213 Taiwan Liposome Company 214 Cellceutix Corporation 215 TVAX Biomedical, LLC 216 CG Therapeutics, Inc. 217 Quintessence Biosciences, Inc. 218 Tautatis Incorporated 219 CureTech Ltd. 220 Lipopharma 221 Nereus Pharmaceuticals, Inc. 222

6

Intestinal Cancer ' Pipeline Revi ew, H2 2012

Viventia Biotechnologies Inc. 223 AVEO Pharmaceuticals, Inc. 224 Merus B.V. 225 Pique Therapeutics 226 Cancer Therapeutics CRC Pty Ltd 227 Isofol Medical AB 228 ISU ABXIS Co.,Ltd. 229 Jiangsu Kanion Pharmaceutical Co., Ltd. 230 Celtic Pharmaceutical Holdings L.P. 231 VectorLogics, Inc. 232 Gliknik, Inc. 233 EyeGene, Inc. 234 ISA Pharmaceuticals B.V. 235 Regulon Inc. 236 ImQuest Life Sciences 237 TAU Therapeutics, LLC 238 Gradalis Inc. 239 FunZyme BioTechnologies S.A. 240 CytomX, LLC. 241 Intestinal Cancer ' Therapeutics Assessment 242 Assessment by Monotherapy Products 242 Assessment by Combination Products 243 RPI-4610 - Drug Profile 244 GM-CT-01 - Drug Profile 245 OncoVAX - Drug Profile 247 rosuvastatin calcium - Drug Profile 249 aspirin - Drug Profile 250 5-Fluorouracil + Leucovorin Calcium + Oxaliplatin + Bevacizumab - Drug Profile 252 CAPOX + Bevacizumab - Drug Profile 254 Bev-FOLFOX - Drug Profile 256 FOLF-CB - Drug Profile 258

7

Intestinal Cancer ' Pipeline Revi ew, H2 2012

Erbitux + BMS-582664 - Drug Profile 260 cetuximab - Drug Profile 262 Panitumumab - Drug Profile 263 Carboplatin + 5-Fluorouracil + Leucovorin - Drug Profile 264 Fluorouracil + Folinic Acid + Capecitabine - Drug Profile 266 FOLFOX-4 + Cetuximab - Drug Profile 268 Cetuximab + FOLFIRI - Drug Profile 270 Radiation Therapy + Fluorouracil + Mitomycin C + Cisplatin - Drug Profile 272 5-Fluorouracil + L-Leucovorin - Drug Profile 274 Eflornithine + Sulindac - Drug Profile 275 tegafur + uracil - Drug Profile 276 Fluorouracil + Levamisole Hydrochloride - Drug Profile 277 Fluorouracil + Leucovorin + Levamisole - Drug Profile 278 5-Fluorouracil + Leucovorin + Radiation Therapy - Drug Profile 280 Fluorouracil + Leucovorin Calcium 1 - Drug Profile 282 Capecitabine + Oxaliplatin - Drug Profile 283 Fluorouracil + Semustine + Vincristine - Drug Profile 284 UFT + Krestin - Drug Profile 286 UFT + Leucovorin + Krestin - Drug Profile 287 Tegafur + Uracil + Leucovorin + Polysaccharide-K - Drug Profile 289 OxCap + Panitumumab - Drug Profile 291 Hepatic Arterial Infusion 5-FU + FOLFOX + Bevacizumab - Drug Profile 293 Propranolol + Etodolac - Drug Profile 295 OxMdG + Panitumumab - Drug Profile 296 Brivanib + Erbitux - Drug Profile 298 5-Fluorouracil + Folinic Acid + CPT-11 - Drug Profile 300 S-1 + Oxaliplatin - Drug Profile 302 5-Fluorouracil + Uracil-Tegafur + Leucovorin - Drug Profile 304 Tegafur + Uracil + Krestin - Drug Profile 306 Uracil + Tegafur + Leucovorin - Drug Profile 307 XELOXA-A - Drug Profile 308

8

Intestinal Cancer ' Pipeline Revi ew, H2 2012

Cisplatin + Fluorouracil + Mitomycin C + Radiation Therapy - Drug Profile 310 Oxaliplatin + FluoroPyrimidine + Panitumumab - Drug Profile 311 Oxaliplatin + Leucovorin Calcium + 5-FU - Drug Profile 313 Bevacizumab + Cetuximab + Fluorouracil + Irinotecan + Leucovorin Calcium + Oxaliplatin - Drug Profile 315 C225 + Fluorouracil + Irinotecan Hydrochloride + Leucovorin Calcium - Drug Profile 317 Floxuridine + Dexamethasone + Leucovorin - Drug Profile 319 Bevacizumab + Fluorouracil + Irinotecan Hydrochloride + Leucovorin Calcium + Oxaliplatin - Drug Profile 321 Bevacizumab + FOLFOX Regimen + Capecitabine + Fluorouracil + Leucovorin Calcium + Oxaliplatin - Drug Profile 324 FOLFOX Regimen + Fluorouracil + Leucovorin Calcium + Oxaliplatin - Drug Profile 327 FOLFIRI - Drug Profile 329 5-Fluorouracil + Isovorin - Drug Profile 331 Avastin + Tarceva - Drug Profile 332 FOLFOX 4 - Drug Profile 335 Ropivacaine + Opioid - Drug Profile 336 Lubiprostone + PEG - Drug Profile 337 Tegafur-Uracil + Leucovorin Calcium - Drug Profile 338 Intestinal Cancer Therapeutics ' Drug Profile Updates 339 Intestinal Cancer Therapeutics ' Discontinued Products 350 Intestinal Cancer Therapeutics - Dormant Products 357 Intestinal Cancer ' Product Development Milestones 401 Featured News & Press Releases 401 Appendix 407 Methodology 407 Coverage 407 Secondary Research 407 Primary Research 407 Expert Panel Validation 407 Contact Us 408

9

Intestinal Cancer ' Pipeline Revi ew, H2 2012

Disclaimer 408

List of Tables Number of Products Under Development for Intestinal Cancer, H2 2012 20 Products under Development for Intestinal Cancer ' Comparative Analysis, H2 2012 21 Number of Products under Development by Companies, H2 2012 23 Number of Products under Development by Companies, H2 2012 (Contd..1) 24 Number of Products under Development by Companies, H2 2012 (Contd..2) 25 Number of Products under Development by Companies, H2 2012 (Contd..3) 26 Number of Products under Development by Companies, H2 2012 (Contd..4) 27 Number of Products under Development by Companies, H2 2012 (Contd..5) 28 Number of Products under Development by Companies, H2 2012 (Contd..6) 29 Number of Products under Development by Companies, H2 2012 (Contd..7) 30 Number of Products under Development by Companies, H2 2012 (Contd..8) 31 Number of Products under Development by Companies, H2 2012 (Contd..9) 32 Number of Products under Development by Companies, H2 2012 (Contd..10) 33 Number of Products under Development by Companies, H2 2012 (Contd..11) 34 Number of Products under Investigation by Universities/Institutes, H2 2012 36 Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 37 Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 38 Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 39 Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 40 Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 41 Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 42 Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 43 Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 44 Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 45 Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 46

10

Intestinal Cancer ' Pipeline Revi ew, H2 2012

Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 47 Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 48 Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 49 Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 50 Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 51 Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 52 Comparative Analysis by Late Stage Development, H2 2012 53 Comparative Analysis by Mid Clinical Stage Development, H2 2012 54 Comparative Analysis by Early Clinical Stage Development, H2 2012 55 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 56 Products under Development by Companies, H2 2012 57 Products under Development by Companies, H2 2012 (Contd..1) 58 Products under Development by Companies, H2 2012 (Contd..2) 59 Products under Development by Companies, H2 2012 (Contd..3) 60 Products under Development by Companies, H2 2012 (Contd..4) 61 Products under Development by Companies, H2 2012 (Contd..5) 62 Products under Development by Companies, H2 2012 (Contd..6) 63 Products under Development by Companies, H2 2012 (Contd..7) 64 Products under Development by Companies, H2 2012 (Contd..8) 65 Products under Development by Companies, H2 2012 (Contd..9) 66 Products under Development by Companies, H2 2012 (Contd..10) 67 Products under Development by Companies, H2 2012 (Contd..11) 68 Products under Development by Companies, H2 2012 (Contd..12) 69 Products under Development by Companies, H2 2012 (Contd..13) 70 Products under Development by Companies, H2 2012 (Contd..14) 71 Products under Development by Companies, H2 2012 (Contd..15) 72 Products under Development by Companies, H2 2012 (Contd..16) 73 Products under Investigation by Universities/Institutes, H2 2012 74 Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 75 Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 76 Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 77

11

Intestinal Cancer ' Pipeline Revi ew, H2 2012

Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 78 Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 79 Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 80 Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 81 Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 82 Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 83 Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 84 Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 85 Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 86 Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 87 Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 88 Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 89 Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 90 Products under Investigation by Universities/Institutes, H2 2012 (Contd..17) 91 Products under Investigation by Universities/Institutes, H2 2012 (Contd..18) 92 Products under Investigation by Universities/Institutes, H2 2012 (Contd..19) 93 Products under Investigation by Universities/Institutes, H2 2012 (Contd..20) 94 Products under Investigation by Universities/Institutes, H2 2012 (Contd..21) 95 Products under Investigation by Universities/Institutes, H2 2012 (Contd..22) 96 Products under Investigation by Universities/Institutes, H2 2012 (Contd..23) 97 Products under Investigation by Universities/Institutes, H2 2012 (Contd..24) 98 Products under Investigation by Universities/Institutes, H2 2012 (Contd..25) 99 Products under Investigation by Universities/Institutes, H2 2012 (Contd..26) 100 Products under Investigation by Universities/Institutes, H2 2012 (Contd..27) 101 Products under Investigation by Universities/Institutes, H2 2012 (Contd..28) 102 Products under Investigation by Universities/Institutes, H2 2012 (Contd..29) 103 Products under Investigation by Universities/Institutes, H2 2012 (Contd..30) 104 Products under Investigation by Universities/Institutes, H2 2012 (Contd..31) 105 Products under Investigation by Universities/Institutes, H2 2012 (Contd..32) 106 Products under Investigation by Universities/Institutes, H2 2012 (Contd..33) 107 Products under Investigation by Universities/Institutes, H2 2012 (Contd..34) 108

12

Intestinal Cancer ' Pipeline Revi ew, H2 2012

Products under Investigation by Universities/Institutes, H2 2012 (Contd..35) 109 Johnson & Johnson, H2 2012 110 F. Hoffmann-La Roche Ltd., H2 2012 111 Kyowa Hakko Kirin Co., Ltd., H2 2012 112 Abbott Laboratories, H2 2012 113 Amgen Inc., H2 2012 114 AstraZeneca PLC, H2 2012 115 Eli Lilly and Company, H2 2012 116 Viralytics Ltd., H2 2012 117 GlaxoSmithKline plc, H2 2012 118 Bioniche Life Sciences, Inc., H2 2012 119 Tekmira Pharmaceuticals Corp., H2 2012 120 Gilead Sciences, Inc., H2 2012 121 Daiichi Sankyo Company, Ltd, H2 2012 122 AbGenomics International, Inc., H2 2012 123 Oxford BioMedica plc, H2 2012 124 YM BioSciences Inc., H2 2012 125 Celltrion, Inc., H2 2012 126 Prolexys Pharmaceuticals, Inc., H2 2012 127 Bio-Path Holdings, Inc., H2 2012 128 BioSante Pharmaceuticals, Inc., H2 2012 129 Histogen, Inc., H2 2012 130 Novartis AG, H2 2012 131 Geistlich Pharma AG, H2 2012 132 Aphios Corporation, H2 2012 133 Astellas Pharma Inc., H2 2012 134 Chong Kun Dang Pharmaceutical, H2 2012 135 Eisai Co., Ltd., H2 2012 136 Nippon Kayaku Co., Ltd., H2 2012 137 Taiho Pharmaceutical Co., Ltd., H2 2012 138 Teva Pharmaceutical Industries Limited, H2 2012 139

13

Intestinal Cancer ' Pipeline Revi ew, H2 2012

Yakult Honsha Co., Ltd., H2 2012 140 Enzon Pharmaceuticals, Inc., H2 2012 141 Alfacell Corporation, H2 2012 142 Bayer AG, H2 2012 143 4SC AG, H2 2012 144 Neogenix Oncology Corporation, H2 2012 145 Alchemia Limited, H2 2012 146 EntreMed, Inc., H2 2012 147 Celldex Therapeutics, Inc., H2 2012 148 Enzo Biochem, Inc., H2 2012 149 AEterna Zentaris Inc., H2 2012 150 ImmunoCellular Therapeutics, Ltd., H2 2012 151 IMMUNOMEDICS, INC, H2 2012 152 Idera Pharmaceuticals, Inc., H2 2012 153 Lorus Therapeutics Inc, H2 2012 154 Bio-Bridge Science, Inc., H2 2012 155 Bionomics Limited, H2 2012 156 Neuren Pharmaceuticals Limited, H2 2012 157 Northwest Biotherapeutics, Inc., H2 2012 158 Novogen Limited, H2 2012 159 Cleveland BioLabs, Inc., H2 2012 160 Compugen Ltd., H2 2012 161 Paladin Labs Inc., H2 2012 162 Patrys Limited, H2 2012 163 Critical Outcome Technologies Inc., H2 2012 164 Curis, Inc., H2 2012 165 Cytokinetics, Inc, H2 2012 166 Telik, Inc., H2 2012 167 Poniard Pharmaceuticals, Inc., H2 2012 168 Regeneron Pharmaceuticals, Inc., H2 2012 169 Dendreon Corporation, H2 2012 170

14

Intestinal Cancer ' Pipeline Revi ew, H2 2012

Choongwae Pharma Corp, H2 2012 171 Green Cross Corporation, H2 2012 172 MOLOGEN AG, H2 2012 173 Innocell Corporation, H2 2012 174 CrystalGenomics, Inc., H2 2012 175 BioAlliance Pharma SA, H2 2012 176 Sareum Holdings plc, H2 2012 177 Transgene Biotek Ltd, H2 2012 178 Rexahn Pharmaceuticals, Inc., H2 2012 179 MabVax Therapeutics, Inc., H2 2012 180 Oryzon, H2 2012 181 Antisense Pharma GmbH, H2 2012 182 Chipscreen Biosciences Ltd, H2 2012 183 Supratek Pharma Inc., H2 2012 184 Bionucleon Srl, H2 2012 185 Actinium Pharmaceuticals, Inc., H2 2012 186 Actis Biologics, Inc, H2 2012 187 Multimmune GmbH, H2 2012 188 Nerviano Medical Sciences S.r.l., H2 2012 189 Med Discovery SA, H2 2012 190 immatics biotechnologies GmbH, H2 2012 191 Provecs Medical GmbH, H2 2012 192 Alethia Biotherapeutics Inc., H2 2012 193 Coronado Biosciences, Inc., H2 2012 194 MacroGenics, Inc., H2 2012 195 ACT Biotech, Inc., H2 2012 196 OncoMed Pharmaceuticals, Inc., H2 2012 197 PledPharma AB, H2 2012 198 Boston Biomedical, Inc., H2 2012 199 DanDrit Biotech A/S, H2 2012 200 Assessment by Monotherapy Products, H2 2012 246

15

Intestinal Cancer ' Pipeline Revi ew, H2 2012

Assessment by Combination Products, H2 2012 247 Intestinal Cancer Therapeutics ' Drug Profile Updates 343 Intestinal Cancer Therapeutics ' Discontinued Products 354 Intestinal Cancer Therapeutics ' Discontinued Products (Contd..1) 355 Intestinal Cancer Therapeutics ' Discontinued Products (Contd..2) 356 Intestinal Cancer Therapeutics ' Discontinued Products (Contd..3) 357 Intestinal Cancer Therapeutics ' Discontinued Products (Contd..4) 358 Intestinal Cancer Therapeutics ' Discontinued Products (Contd..5) 359 Intestinal Cancer Therapeutics ' Discontinued Products (Contd..6) 360 Intestinal Cancer Therapeutics ' Dormant Products 361 Intestinal Cancer Therapeutics ' Dormant Products (Contd..1) 362 Intestinal Cancer Therapeutics ' Dormant Products (Contd..2) 363 Intestinal Cancer Therapeutics ' Dormant Products (Contd..3) 364 Intestinal Cancer Therapeutics ' Dormant Products (Contd..4) 365 Intestinal Cancer Therapeutics ' Dormant Products (Contd..5) 366 Intestinal Cancer Therapeutics ' Dormant Products (Contd..6) 367 Intestinal Cancer Therapeutics ' Dormant Products (Contd..7) 368 Intestinal Cancer Therapeutics ' Dormant Products (Contd..8) 369 Intestinal Cancer Therapeutics ' Dormant Products (Contd..9) 370 Intestinal Cancer Therapeutics ' Dormant Products (Contd..10) 371 Intestinal Cancer Therapeutics ' Dormant Products (Contd..11) 372 Intestinal Cancer Therapeutics ' Dormant Products (Contd..12) 373 Intestinal Cancer Therapeutics ' Dormant Products (Contd..13) 374 Intestinal Cancer Therapeutics ' Dormant Products (Contd..14) 375 Intestinal Cancer Therapeutics ' Dormant Products (Contd..15) 376 Intestinal Cancer Therapeutics ' Dormant Products (Contd..16) 377 Intestinal Cancer Therapeutics ' Dormant Products (Contd..17) 378 Intestinal Cancer Therapeutics ' Dormant Products (Contd..18) 379 Intestinal Cancer Therapeutics ' Dormant Products (Contd..19) 380 Intestinal Cancer Therapeutics ' Dormant Products (Contd..20) 381 Intestinal Cancer Therapeutics ' Dormant Products (Contd..21) 382

16

Intestinal Cancer ' Pipeline Revi ew, H2 2012

Intestinal Cancer Therapeutics ' Dormant Products (Contd..22) 383 Intestinal Cancer Therapeutics ' Dormant Products (Contd..23) 384 Intestinal Cancer Therapeutics ' Dormant Products (Contd..24) 385 Intestinal Cancer Therapeutics ' Dormant Products (Contd..25) 386 Intestinal Cancer Therapeutics ' Dormant Products (Contd..26) 387 Intestinal Cancer Therapeutics ' Dormant Products (Contd..27) 388 Intestinal Cancer Therapeutics ' Dormant Products (Contd..28) 389 Intestinal Cancer Therapeutics ' Dormant Products (Contd..29) 390 Intestinal Cancer Therapeutics ' Dormant Products (Contd..30) 391 Intestinal Cancer Therapeutics ' Dormant Products (Contd..31) 392 Intestinal Cancer Therapeutics ' Dormant Products (Contd..32) 393 Intestinal Cancer Therapeutics ' Dormant Products (Contd..33) 394 Intestinal Cancer Therapeutics ' Dormant Products (Contd..34) 395 Intestinal Cancer Therapeutics ' Dormant Products (Contd..35) 396 Intestinal Cancer Therapeutics ' Dormant Products (Contd..36) 397 Intestinal Cancer Therapeutics ' Dormant Products (Contd..37) 398 Intestinal Cancer Therapeutics ' Dormant Products (Contd..38) 399 Intestinal Cancer Therapeutics ' Dormant Products (Contd..39) 400 Intestinal Cancer Therapeutics ' Dormant Products (Contd..40) 401 Intestinal Cancer Therapeutics ' Dormant Products (Contd..41) 402 Intestinal Cancer Therapeutics ' Dormant Products (Contd..42) 403 Intestinal Cancer Therapeutics ' Dormant Products (Contd..43) 404

List of Figures Number of Products under Development for Intestinal Cancer, H2 2012 20 Products under Development for Intestinal Cancer ' Comparative Analysis, H2 2012 21 Products under Development by Companies, H2 2012 22 Products under Investigation by Universities/Institutes, H2 2012 35

17

Intestinal Cancer ' Pipeline Revi ew, H2 2012

Late Stage Products, H2 2012 53 Mid Clinical Stage Products, H2 2012 54 Early Clinical Stage Products, H2 2012 55 Discovery and Pre-Clinical Stage Products, H2 2012 56 Assessment by Monotherapy Products, H2 2012 246 Assessment by Combination Products, H2 2012 247

Related Documents
Central Nervous System (CNS) Tumor - Pipeline Review, H2 2012
Central Nervous System (CNS) Tumor - Pipeline Review, H2 2012 Summary Global Markets Direct's, 'Central Nervous System (CNS) Tumor - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Central Nervous System (CNS) Tumor, complete with latest updates, and special features on late-stage and discontinued ...

Solid Tumor - Pipeline Review, H2 2012
Solid Tumor - Pipeline Review, H2 2012 Summary Global Markets Direct's, 'Solid Tumor - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Solid Tumor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic ...

Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H2, 2012
Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H2, 2012 Summary GlobalData's clinical trial report, 'Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H2, 2012" provides data on the Chemotherapy Induced Nausea and Vomiting clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Chemotherapy Induced ...

Psychiatric Disorders - Pipeline Review, H2 2012
Psychiatric Disorders - Pipeline Review, H2 2012 Summary Global Markets Direct's, 'Psychiatric Disorders - Pipeline

18

Intestinal Cancer ' Pipeline Revi ew, H2 2012

Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Psychiatric Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key ...

Osteopenia - Pipeline Review, H2 2012
Osteopenia - Pipeline Review, H2 2012 Summary Global Markets Direct's, 'Osteopenia - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Osteopenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic ...

Trauma - Pipeline Review, H2 2012
Trauma - Pipeline Review, H2 2012 Summary Global Markets Direct's, 'Trauma - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Trauma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development ...

Left Ventricular Dysfunction - Pipeline Review, H2 2012
Left Ventricular Dysfunction - Pipeline Review, H2 2012 Summary Global Markets Direct's, 'Left Ventricular Dysfunction - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Left Ventricular Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. ...

Degenerative Disc Disease - Pipeline Review, H2 2012
Degenerative Disc Disease - Pipeline Review, H2 2012 Summary Global Markets Direct's, 'Degenerative Disc Disease - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Degenerative Disc Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also ...

Cellulite - Pipeline Review, H2 2012
Cellulite - Pipeline Review, H2 2012 Summary Global Markets Direct's, 'cellulite - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for

19

Intestinal Cancer ' Pipeline Revi ew, H2 2012

cellulite, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic ...

Microalbuminuria - Pipeline Review, H2 2012
Microalbuminuria - Pipeline Review, H2 2012 Summary Global Markets Direct's, 'Microalbuminuria - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Microalbuminuria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved ...

20

You're Reading a Free Preview

Download
scribd
/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->